Healthy adults
Conditions
Interventions
Ingestion of 150 mg Gnetinc C resveratrol daily for 2 weeks
Ingestion of 150 mg placebo daily for 2 weeks
Sponsors
Aichi Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Drinking three times or less a week, normal liver and renal function that has been confirmed in a medical examination within one year, and consent by explanation and agreement documents.
Exclusion criteria
Exclusion criteria: Any of the following: currently receiving a drug therapy, currently having chronic diseases such as heart, lung, kidney, gastrointestinal, and inflammatory diseases, suffering from invasive cancer within five years, suffering from non-invasive cancer within a year, a history of smoking within one year, taking foods which contain resveratrol, supplements, vitamins within 2 weeks, pregnant or lactating, and a history of hypersensitivity to resveratrol or supplements including resveratrol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Influence of oral administration of Gnetinc C resveratrol on the expression of NK related antigens and NK cell function during 4 weeks after its start | — |
Secondary
| Measure | Time frame |
|---|---|
| Gnetin C resveratrol related toxicity during 4 weeks after its oral administration Influence of oral administration of Gnetin C resveratrol on the serum and urine antioxidant function and uric acid metabolism functionduring 4 weeks after its start | — |
Countries
Japan
Contacts
Public ContactAkiyoshi Takami
Aichi Medical University School of Medicine Division of Hematology, Department of Internal Medicine
Outcome results
None listed